• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
MYX
Click for more information
7.18% $4.48

MAYNE PHARMA GROUP LIMITED - Announcements

Market Cap $393.8M  ! watchlist Created with Sketch. Add to my watchlist

Mayne Pharma Group Limited is an Australia-based specialty pharmaceutical company focused... Mayne Pharma Group Limited is an Australia-based specialty pharmaceutical company focused on commercializing novel pharmaceuticals. The Company also provides contract development and manufacturing services to clients worldwide. The Company’s segments include Women’s Health, Dermatology, and International. The Women’s Health segment distributes women’s health branded products in the United States. This segment includes NEXTSTELLIS, ANNOVERA, BIJUVA, IMVEXXY and branded pre-natal vitamins. The Dermatology segment distributes established dermatology products in the United States. The International segment is engaged in the manufacture and sale of branded and generic pharmaceutical products globally and the provision of contract development and manufacturing services to third party customers. The Company's products include ACTIKERALL Solution, ASTRIX Capsules and Tablets, MAGNOPLASM Paste and SPLINTEX Splinter Removal Gel, and ANNOVERA Vaginal Ring, among others.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
MYX Change in substantial holding14/03/19
MYX 2019 Half Year Investor PresentationPRICE SENSITIVE22/02/19
MYX 2019 Half Year Media ReleasePRICE SENSITIVE22/02/19
MYX Half Year AccountsPRICE SENSITIVE22/02/19
MYX Mayne Pharma announces new indication for Kapanol by TGA19/02/19
MYX Lexette (halobetasol) foam now launched in the US13/02/19
MYX Tolsura (SUBA-itraconazole) capsule now launched in the USPRICE SENSITIVE30/01/19
MYX Change of Director's Interest Notice31/12/18
MYX Employee option exercise28/12/18
MYX Change of Director's Interest Notice24/12/18
MYX MYX extends debt facility and adds receivables facility20/12/18
MYX MYX announces US commercial rights for SUBA-itra in BCCNS18/12/18
MYX Ceasing to be a substantial holder14/12/18
MYX FDA approval of Tolsura (SUBA-itraconazole) capsulesPRICE SENSITIVE12/12/18
MYX Change of Director's Interest Notice10/12/18
MYX Appendix 3B07/12/18
MYX Becoming a substantial holder06/12/18
MYX Final Director's Interest Notice29/11/18
MYX Results of 2018 AGM29/11/18
MYX 2018 AGM CEO's SpeechPRICE SENSITIVE29/11/18
MYX 2018 AGM Chairman's AddressPRICE SENSITIVE29/11/18
MYX Appendix 3B31/10/18
MYX Retirement of Director29/10/18
MYX Notice of Annual General Meeting / Proxy Form29/10/18
MYX Investor Presentation Acquisition of halobetasol foam26/10/18
MYX MYX announces acquisition of FDA approved halobetasol foam26/10/18
MYX Appendix 4G and 2018 Corporate Governance Statement19/10/18
MYX 2018 Annual Report12/10/18
MYX Appendix 3B, employee option exercise and option lapse10/10/18
MYX Change in substantial holding09/10/18
MYX Appendix 3B, employee option exercise and option lapse11/09/18
MYX Change in substantial holding31/08/18
MYX 2018 Full Year Results Investor PresentationPRICE SENSITIVE24/08/18
MYX 2018 Full Year Results Media ReleasePRICE SENSITIVE24/08/18
MYX Full Year Statutory AccountsPRICE SENSITIVE24/08/18
MYX Appendix 3B27/07/18
MYX Mayne Pharma acquires generic Efudex in the USPRICE SENSITIVE23/07/18
MYX Lapse of employee options and option exercise16/07/18
MYX Initial Director's Interest Notice28/06/18
MYX Mayne Pharma further strengthens Board with new Director28/06/18
MYX Appendix 3B20/06/18
MYX Appendix 3B15/06/18
MYX Ceasing to be a substantial holder07/06/18
MYX Appendix 3B06/06/18
MYX Revised Securities Trading Policy31/05/18
MYX Initial Director's Interest Notice30/05/18
MYX Mayne Pharma strengthens Board with new Director30/05/18
MYX SUBA-Itraconazole NDA accepted for review by US FDAPRICE SENSITIVE02/05/18
MYX Appendix 3B01/05/18
MYX Mayne Pharma opens new US manufacturing facilityPRICE SENSITIVE18/04/18
MYX Mayne Pharma launches Amiodarone 200mg tablets in the USPRICE SENSITIVE17/04/18
MYX Appendix 3B10/04/18
MYX Appendix 3B09/04/18
MYX Change in substantial holding28/03/18
MYX Mayne Pharma launches generic Quartette in the US27/03/18
MYX Appendix 3B and lapse of employee options20/03/18
MYX Mayne Pharma's generic NuvaRing accepted for filing by FDAPRICE SENSITIVE20/03/18
MYX Mayne Pharma launches doxycycline IR capsules in the USPRICE SENSITIVE16/03/18
MYX First generic launch of Ritalin LA 10mg capsules in the USPRICE SENSITIVE01/03/18
MYX Becoming a substantial holder27/02/18
MYX 2018 Half Year Investor PresentationPRICE SENSITIVE23/02/18
MYX 2018 Half Year Media ReleasePRICE SENSITIVE23/02/18
MYX Half Yearly Report and AccountsPRICE SENSITIVE23/02/18
MYX Appendix 3B20/02/18
MYX Employee share scheme buyback final notice19/02/18
MYX Appendix 3C - Employee Loan Scheme Buy Back02/02/18
MYX Change of Director's Interest Notice22/12/17
MYX Appendix 3B15/12/17
MYX Change of Director's Interest Notice07/12/17
MYX Appendix 3B07/12/17
MYX Appendix 3B30/11/17
MYX Results of Meeting28/11/17
MYX 2017 AGM Presentation28/11/17
MYX 2017 CEO's SpeechPRICE SENSITIVE28/11/17
MYX 2017 AGM Chairman's Speech28/11/17
MYX Mayne Pharma launches clozapine tablets in the USPRICE SENSITIVE09/11/17
MYX Appendix 3B02/11/17
MYX Notice of Annual General Meeting/Proxy Form20/10/17
MYX Appendix 4G19/10/17
MYX 2017 Corporate Governance Statement19/10/17
MYX 2017 Annual Report19/10/17
MYX Appendix 3B11/10/17
MYX Mayne Pharma adds two products to its Australian portfolioPRICE SENSITIVE15/09/17
MYX Appendix 3B and lapse of employee options08/09/17
MYX Full Year Statutory Accounts30/08/17
MYX Change of Director's Interest Notice29/08/17
MYX Ceasing to be a substantial holder28/08/17
MYX 2017 Full Year Results Investor Presentation25/08/17
MYX 2017 Full Year Results Media Release25/08/17
MYX Preliminary Final ReportPRICE SENSITIVE25/08/17
MYX Ceasing to be a substantial holder from CBA16/08/17
MYX Change in substantial holding from CBA14/08/17
MYX Change in substantial holding08/08/17
MYX Mayne Pharma market updatePRICE SENSITIVE08/08/17
MYX Change in substantial holding from CBA31/07/17
MYX Appendix 3B14/07/17
MYX Appendix 3B27/06/17
MYX Change of Director's Interest Notice27/06/17
MYX FDA approval and first generic launch of Acticlate tabletsPRICE SENSITIVE15/06/17
MYX Appendix 3B09/06/17
MYX Change in substantial holding
14/03/19
MYX 2019 Half Year Investor Presentation
22/02/19PRICE SENSITIVE
MYX 2019 Half Year Media Release
22/02/19PRICE SENSITIVE
MYX Half Year Accounts
22/02/19PRICE SENSITIVE
MYX Mayne Pharma announces new indication for Kapanol by TGA
19/02/19
MYX Lexette (halobetasol) foam now launched in the US
13/02/19
MYX Tolsura (SUBA-itraconazole) capsule now launched in the US
30/01/19PRICE SENSITIVE
MYX Change of Director's Interest Notice
31/12/18
MYX Employee option exercise
28/12/18
MYX Change of Director's Interest Notice
24/12/18
MYX MYX extends debt facility and adds receivables facility
20/12/18
MYX MYX announces US commercial rights for SUBA-itra in BCCNS
18/12/18
MYX Ceasing to be a substantial holder
14/12/18
MYX FDA approval of Tolsura (SUBA-itraconazole) capsules
12/12/18PRICE SENSITIVE
MYX Change of Director's Interest Notice
10/12/18
MYX Appendix 3B
07/12/18
MYX Becoming a substantial holder
06/12/18
MYX Final Director's Interest Notice
29/11/18
MYX Results of 2018 AGM
29/11/18
MYX 2018 AGM CEO's Speech
29/11/18PRICE SENSITIVE
MYX 2018 AGM Chairman's Address
29/11/18PRICE SENSITIVE
MYX Appendix 3B
31/10/18
MYX Retirement of Director
29/10/18
MYX Notice of Annual General Meeting / Proxy Form
29/10/18
MYX Investor Presentation Acquisition of halobetasol foam
26/10/18
MYX MYX announces acquisition of FDA approved halobetasol foam
26/10/18
MYX Appendix 4G and 2018 Corporate Governance Statement
19/10/18
MYX 2018 Annual Report
12/10/18
MYX Appendix 3B, employee option exercise and option lapse
10/10/18
MYX Change in substantial holding
09/10/18
MYX Appendix 3B, employee option exercise and option lapse
11/09/18
MYX Change in substantial holding
31/08/18
MYX 2018 Full Year Results Investor Presentation
24/08/18PRICE SENSITIVE
MYX 2018 Full Year Results Media Release
24/08/18PRICE SENSITIVE
MYX Full Year Statutory Accounts
24/08/18PRICE SENSITIVE
MYX Appendix 3B
27/07/18
MYX Mayne Pharma acquires generic Efudex in the US
23/07/18PRICE SENSITIVE
MYX Lapse of employee options and option exercise
16/07/18
MYX Initial Director's Interest Notice
28/06/18
MYX Mayne Pharma further strengthens Board with new Director
28/06/18
MYX Appendix 3B
20/06/18
MYX Appendix 3B
15/06/18
MYX Ceasing to be a substantial holder
07/06/18
MYX Appendix 3B
06/06/18
MYX Revised Securities Trading Policy
31/05/18
MYX Initial Director's Interest Notice
30/05/18
MYX Mayne Pharma strengthens Board with new Director
30/05/18
MYX SUBA-Itraconazole NDA accepted for review by US FDA
02/05/18PRICE SENSITIVE
MYX Appendix 3B
01/05/18
MYX Mayne Pharma opens new US manufacturing facility
18/04/18PRICE SENSITIVE
MYX Mayne Pharma launches Amiodarone 200mg tablets in the US
17/04/18PRICE SENSITIVE
MYX Appendix 3B
10/04/18
MYX Appendix 3B
09/04/18
MYX Change in substantial holding
28/03/18
MYX Mayne Pharma launches generic Quartette in the US
27/03/18
MYX Appendix 3B and lapse of employee options
20/03/18
MYX Mayne Pharma's generic NuvaRing accepted for filing by FDA
20/03/18PRICE SENSITIVE
MYX Mayne Pharma launches doxycycline IR capsules in the US
16/03/18PRICE SENSITIVE
MYX First generic launch of Ritalin LA 10mg capsules in the US
01/03/18PRICE SENSITIVE
MYX Becoming a substantial holder
27/02/18
MYX 2018 Half Year Investor Presentation
23/02/18PRICE SENSITIVE
MYX 2018 Half Year Media Release
23/02/18PRICE SENSITIVE
MYX Half Yearly Report and Accounts
23/02/18PRICE SENSITIVE
MYX Appendix 3B
20/02/18
MYX Employee share scheme buyback final notice
19/02/18
MYX Appendix 3C - Employee Loan Scheme Buy Back
02/02/18
MYX Change of Director's Interest Notice
22/12/17
MYX Appendix 3B
15/12/17
MYX Change of Director's Interest Notice
07/12/17
MYX Appendix 3B
07/12/17
MYX Appendix 3B
30/11/17
MYX Results of Meeting
28/11/17
MYX 2017 AGM Presentation
28/11/17
MYX 2017 CEO's Speech
28/11/17PRICE SENSITIVE
MYX 2017 AGM Chairman's Speech
28/11/17
MYX Mayne Pharma launches clozapine tablets in the US
09/11/17PRICE SENSITIVE
MYX Appendix 3B
02/11/17
MYX Notice of Annual General Meeting/Proxy Form
20/10/17
MYX Appendix 4G
19/10/17
MYX 2017 Corporate Governance Statement
19/10/17
MYX 2017 Annual Report
19/10/17
MYX Appendix 3B
11/10/17
MYX Mayne Pharma adds two products to its Australian portfolio
15/09/17PRICE SENSITIVE
MYX Appendix 3B and lapse of employee options
08/09/17
MYX Full Year Statutory Accounts
30/08/17
MYX Change of Director's Interest Notice
29/08/17
MYX Ceasing to be a substantial holder
28/08/17
MYX 2017 Full Year Results Investor Presentation
25/08/17
MYX 2017 Full Year Results Media Release
25/08/17
MYX Preliminary Final Report
25/08/17PRICE SENSITIVE
MYX Ceasing to be a substantial holder from CBA
16/08/17
MYX Change in substantial holding from CBA
14/08/17
MYX Change in substantial holding
08/08/17
MYX Mayne Pharma market update
08/08/17PRICE SENSITIVE
MYX Change in substantial holding from CBA
31/07/17
MYX Appendix 3B
14/07/17
MYX Appendix 3B
27/06/17
MYX Change of Director's Interest Notice
27/06/17
MYX FDA approval and first generic launch of Acticlate tablets
15/06/17PRICE SENSITIVE
MYX Appendix 3B
09/06/17
refresh Created with Sketch. REFRESH
 
(20min delay)
Last
$4.48 		Change
0.300(7.18%) 		Mkt cap ! $393.8M
Open High Low Value Volume
$4.22 $4.50 $4.18 $1.134M 259.5K

Buyers (Bids)

No. Vol. Price($)
1 708 $4.43
 

Sellers (Offers)

Price($) Vol. No.
$4.50 1182 1
View Market Depth
Last trade - 16.10pm 22/11/2024 (20 minute delay) ?
Last
$4.48 		  Change
0.300 ( 7.09 %)
Open High Low Volume
$4.23 $4.49 $4.17 95547
Last updated 15.59pm 22/11/2024 ?
MYX (ASX) Chart

Top Stories

Week 47 Wrap: HotCopper users' most watched; Brent lifts on Putin's scary letter; RFK dents CSL

Welcome to the end of another week. Let's start with what HotCopper users have been watching and discussing.
To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels Put simply: if 3D Printing is a gold rush, Amaero is selling shovels. Or maybe it's more like sneakers in an arms race.
Dale Gillham's weekly wrap: Sigma-Chemist Warehouse merger creates pharma powerhouse The $8.8 billion dollar merger between Sigma Healthcare and Chemist Warehouse is poised to reshape the Australian pharmacy landscape, consolidating power in the hands of two industry giants. But what does this mean for Australians @ greater access to cheaper medicines or the loss of small, commun...
Panic, paranoia, and gangland politics: HotCopper users react to Dubber's missing $26M HotCopper users have reacted to overnight reports Dubber has seen $26M disappear from its coffers due to organised crime links.
Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects Pan Asia Metals has scored $35 million from a New York private equity firm at the same time as the company's big rebrand push begins.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.